Date: 2016-01-28
Type of information: Loan
Company: Transgene (France)
Investors: European Investment Bank (EIB)
Amount: € 20 million
Funding type: loan
Planned used: This loan will help finance Transgene's new clinical developments for the treatment of infectious diseases, including chronic hepatitis B, virus-induced cancers such as HPV (human papilloma virus) and tuberculosis.
Others: * On January 28, 2016, the European Investment Bank (EIB) and Transgene announced that they have entered into a € 20 million financing agreement. EIB support for the development of Transgene should be seen in the context of the Horizon 2020 initiative, in particular the EU Finance for Innovators programme "InnovFin IDFF" (Infectious Diseases Finance Facility), which offers bespoke products for financing high-risk projects in the field of infectious diseases. This instrument is for financing the development of vaccines, medicines, medical and diagnostic equipment and research infrastructure.
Therapeutic area: Infectious diseases
